Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Gains from Investment Securities (2019 - 2025)

Opus Genetics has reported Gains from Investment Securities over the past 11 years, most recently at $100000.0 for Q3 2025.

  • Quarterly Gains from Investment Securities fell 83.11% to $100000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Mar 2026, down 99.55% year-over-year, with the annual reading at $22.2 million for FY2025, 1526.23% up from the prior year.
  • Gains from Investment Securities was $100000.0 for Q3 2025 at Opus Genetics, down from $22.2 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $22.2 million in Q1 2025 and troughed at $26000.0 in Q4 2023.
  • The 5-year median for Gains from Investment Securities is $259443.0 (2021), against an average of $3.9 million.
  • The largest YoY upside for Gains from Investment Securities was 8479.82% in 2025 against a maximum downside of 83.11% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $128000.0 in 2021, then surged by 30.47% to $167000.0 in 2022, then tumbled by 84.43% to $26000.0 in 2023, then skyrocketed by 2177.78% to $592222.0 in 2024, then plummeted by 83.11% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRD's Gains from Investment Securities are $100000.0 (Q3 2025), $22.2 million (Q2 2025), and $22.2 million (Q1 2025).